Biotech

Agatica, provider of medical cashless payment app “Tamayen Pay,” raises a total of 45.8 million yen in seed round

Agatica Inc., which promotes cashless medical care, is pleased to announce that it has raised a total of 45.8 million yen through J-KISS-type stock acquisition rights underwritten by QXLV (Quantum Leap Ventures) and a third-party allotment of new shares underwritten by multiple individual investors. The funds raised will be used for product development, etc. This will further accelerate the shift to cashless and digital transformation in the medical industry. Although cashless payments are becoming more common in Japan, medical institutions are still slow to adopt cashless payment methods, and cash payments are still the norm. In addition, due to the delay in digitalization, patients are dissatisfied with making reservations over the phone and waiting long hours to pay, and medical institutions are also faced with complicated sales management, excessive workloads,…

Just for You

SoftBank Corp launches “HacoBuddy” to help improve on-site productivity through digital transformation

SoftBank Corp. will begin offering "HacoBuddy," a service for the construction industry that supports digital…

Leading Mark, the provider of “Mikiwame,” raises 1.62 billion yen in funding and simultaneously releases a new product, “Mikiwame Management”

Leading Mark Inc., which provides the HR platform "Mikiwame" to reduce "recruitment mismatch" and "employee…

The Impact of 6G Technology on Japan’s Future Smart Cities

Introduction As the global competition toward 6G technology is on the rise, Japan is distinctly…

Giftpad announces collaboration with Otsuka Pharmaceutical for “Health and Productivity Management Connecting Support ONLINE”

GiftPad Inc., which supports digital transformation for local governments and companies, is pleased to announce…

Latest Biotech

JiMED, a developer of wireless implantable BMI system medical devices, raises 350 million yen in Series A funding

JiMED Inc., a developer of wireless implantable BMI system medical devices, has raised a total of 350 million yen through…

Daiichi Sankyo Acquires Anti-TA-MUC1 Antibody IP from Glycotope

Daiichi Sankyo Company, Ltd  announced  that it will pay Glycotope $132.5 million to acquire intellectual property rights of the anti-tumor-associated…

Join Our Community